Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 3
1989 3
1990 2
1991 4
1994 4
1995 2
1996 2
1997 4
1998 4
1999 6
2000 8
2001 5
2002 8
2003 8
2004 6
2005 4
2006 10
2007 3
2008 7
2009 11
2010 10
2011 11
2012 6
2013 12
2014 15
2015 16
2016 29
2017 20
2018 24
2019 34
2020 36
2021 29
Text availability
Article attribute
Article type
Publication date

Search Results

318 results
Results by year
Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: pignata s. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. Mirza MR, et al. Among authors: pignata s. Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32569725 Review.
Treatment of recurrent ovarian cancer.
Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Pignata S, et al. Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441. Ann Oncol. 2017. PMID: 29232464 Free article. Review.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Among authors: pignata s. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Among authors: pignata s. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. Ann Oncol. 2019. PMID: 31046081 Free article.
PARP inhibitors in ovarian cancer.
Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M. Franzese E, et al. Among authors: pignata s. Cancer Treat Rev. 2019 Feb;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. Epub 2018 Dec 4. Cancer Treat Rev. 2019. PMID: 30543930 Free article. Review.
Treatment of recurrent epithelial ovarian cancer.
Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L. Pignata S, et al. Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500. Cancer. 2019. PMID: 31967680 Free article. Review.
Immunotherapy in cervix cancer.
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Attademo L, et al. Among authors: pignata s. Cancer Treat Rev. 2020 Nov;90:102088. doi: 10.1016/j.ctrv.2020.102088. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32827839 Review.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Matulonis UA, et al. Among authors: pignata s. Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135. Ann Oncol. 2019. PMID: 31046082 Free article. Clinical Trial.
318 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page